A Phase II Study of Anti-BCMA CAR T Cell Therapy for Multiple Myeloma After Stem Cell Transplant and Lenalidomide


Full Title

Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide (BMT CTN 1902)(NMDP)


With CAR T cell therapy, some of a patient’s own T cells (a type of white blood cell) are removed and genetically modified in a laboratory to recognize their own cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body. This approach is a form of immunotherapy. One form of CAR T cell therapy for multiple myeloma, called bb2121, targets a protein on cancer cells called BCMA.

In this study, researchers want to see if bb2121 plus maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back in people with multiple myeloma that has not responded well to an autologous (self) stem cell transplant and maintenance lenalidomide.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma that did not respond well to autologous stem cell transplantation and maintenance therapy with lenalidomide.
  • This study is for people age 18-70.


For more information and to ask about eligibility for this study, please contact the office of Dr. Sergio Giralt at 646-608-3731.




Phase II (phase 2)



ClinicalTrials.gov ID